Literature DB >> 30137552

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis.

Christopher R Holroyd1, Rakhi Seth1, Marwan Bukhari2, Anshuman Malaviya3, Claire Holmes1, Elizabeth Curtis4, Christopher Chan1, Mohammed A Yusuf3, Anna Litwic4,5, Susan Smolen3, Joanne Topliffe3, Sarah Bennett1, Jennifer Humphreys6, Muriel Green7, Jo Ledingham8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30137552     DOI： 10.1093/rheumatology/key208

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  17 in total

1.  Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis.

Authors:  Michael M Ward; Abhijit Dasgupta
Journal:  Rheumatology (Oxford)       Date:  2020-12-01       Impact factor: 7.580

Review 2.  Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review.

Authors:  Winifred Ekezie; Rachael L Murray; Sanjay Agrawal; Ilze Bogdanovica; John Britton; Jo Leonardi-Bee
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

3.  Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications.

Authors:  Sarah Patterson; Gabriela Schmajuk; Michael Evans; Ishita Aggarwal; Zara Izadi; Milena Gianfrancesco; Jinoos Yazdany
Journal:  Jt Comm J Qual Patient Saf       Date:  2019-01-25

Review 4.  Acute exacerbation of interstitial lung disease associated with rheumatic disease.

Authors:  Fabrizio Luppi; Marco Sebastiani; Carlo Salvarani; Elisabeth Bendstrup; Andreina Manfredi
Journal:  Nat Rev Rheumatol       Date:  2021-12-07       Impact factor: 20.543

5.  Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement.

Authors:  Alfredo Aguirre; Jinoos Yazdany
Journal:  J Rheumatol       Date:  2021-11-01       Impact factor: 5.346

6.  Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids.

Authors:  Jun Won Park; Jeffrey R Curtis; Hajeong Lee; Jung-Kyu Lee; Yeong Wook Song; Eun Bong Lee
Journal:  PLoS One       Date:  2020-12-31       Impact factor: 3.240

7.  Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.

Authors:  Adelle S Jee; Robert Sheehy; Peter Hopkins; Tamera J Corte; Christopher Grainge; Lauren K Troy; Karen Symons; Lissa M Spencer; Paul N Reynolds; Sally Chapman; Sally de Boer; Taryn Reddy; Anne E Holland; Daniel C Chambers; Ian N Glaspole; Helen E Jo; Jane F Bleasel; Jeremy P Wrobel; Leona Dowman; Matthew J S Parker; Margaret L Wilsher; Nicole S L Goh; Yuben Moodley; Gregory J Keir
Journal:  Respirology       Date:  2020-11-24       Impact factor: 6.424

Review 8.  Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows.

Authors:  Giulia Cassone; Andreina Manfredi; Caterina Vacchi; Fabrizio Luppi; Francesca Coppi; Carlo Salvarani; Marco Sebastiani
Journal:  J Clin Med       Date:  2020-04-10       Impact factor: 4.241

9.  Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry.

Authors:  Akio Kawabe; Kazuhisa Nakano; Satoshi Kubo; Takeshi Asakawa; Yoshiya Tanaka
Journal:  Arthritis Res Ther       Date:  2020-06-08       Impact factor: 5.156

10.  Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression.

Authors:  Marika Tardella; Marco Di Carlo; Marina Carotti; Andrea Giovagnoni; Fausto Salaffi
Journal:  Clin Rheumatol       Date:  2021-07-27       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.